Scholar Rock Financial Ratios
NASDAQ: SRRKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
42.19-0.01 (-0.02%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Scholar Rock ratio analysis
Return on equity reached -154.0%, meaning Scholar Rock generated -1.54 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.41 versus 0.14 the year before, and the current ratio was 6.95. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Scholar Rock financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Price / sales | — | — | — | 16.25 | 48.47 | 96.83 | 16.52 | — | — |
| Price / book | 20.00 | 12.23 | 6.96 | 2.07 | 5.30 | 5.72 | 3.00 | 3.15 | — |
| Operating margin | — | — | — | -404.8% | -690.5% | -564.0% | -266.2% | — | — |
| Net margin | — | — | — | -405.2% | -700.5% | -561.5% | -248.9% | — | — |
| Free cash flow margin | — | — | — | -403.0% | -701.7% | -417.8% | -323.2% | — | — |
| Return on equity (ROE) | -154.0% | -66.8% | -73.6% | -51.7% | -76.6% | -33.2% | -45.2% | -46.3% | — |
| Return on assets (ROA) | -93.5% | -51.9% | -53.3% | -37.6% | -43.3% | -22.3% | -26.0% | -27.2% | -40.6% |
| Debt / equity | 0.41 | 0.14 | 0.22 | 0.19 | 0.29 | 0.09 | 0.00 | 0.00 | — |
| Current ratio | 6.95 | 9.61 | 8.80 | 9.01 | 4.13 | 8.09 | 5.64 | 5.72 | 11.78 |
| Revenue growth | — | — | — | 76.4% | 22.2% | -24.8% | — | — | — |